Acute pancreatitis during GLP-1 receptor agonist treatment. A case reportdoi:10.15386/cjmed-804Bogdan Augustin ChisDaniela FodorCardiovascular effects of GLP-1 receptor agonist treatment:focus on liraglutide. Haluzík M,Trachta P,Mráz M. Vnitrni Lekarstvi . 2015...
GLP-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in type 2 diabetes patients: a randomised trial AIMS Glucagon-like peptide-1 receptor agonists, commonly used to treat type 2 diabetes, have been associated with an increased risk of acute pancreatitis...
Semaglutide produces significant weight loss in most people with obesity. When should it be prescribed, and what are the pitfalls? Medscape Diabetes & Endocrinology, September 29, 2023 15 GLP-1 Agonists and Suicide Risk: Is Action Needed? Do reports of suicidal thoughts in patients taking GLP...
Cases of pancreatitis have been reported in type 2 diabetes patients treated with GLP-1 (GLP-1R) receptor agonists. To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents. Normal and diabetic...
Hemochromatosis and Cystic Fibrosis Carriers Identify Risk for GLP-1 Agonist Associated Pancreatitisdoi:10.2337/DB18-2296-PUBGLP-1 agonists are widely used ... W West,G Uwaifo - 《Diabetes》 被引量: 0发表: 2018年 A product of immunoreactive trypsinogen and pancreatitis-associated protein as second...
However, the RBP levels were significantly increased in CP compared with that during acute pancreatic inflammation. Moreover, the WNR was significantly higher for AP. Our differential analysis of the serum indicators WBC, NE, RBP, and, WNR in AP and CP is shown in Figure S1. An analysis ...
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide , is a widely used drug for the treatment of type 2 diabetes. Liraglutide is one of sev...
Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing liga
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist an... The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs...
After discharge, the patient's serum triglyceride concentration was aggressively managed with combination anti-lipidemia therapy and his diabetes was subsequently treated with a GLP-1 receptor agonist. There was no recurrence of pancreatitis after 1 year of follow-up. Conclusion: GLP-1 receptor ...